share_log

Gilead Sciences | 8-K: Gilead Sciences Reports Third Quarter 2024 Financial Results

Gilead Sciences | 8-K: Gilead Sciences Reports Third Quarter 2024 Financial Results

吉利德科学 | 8-K：吉利德科学公布2024年第三季度财务业绩
美股SEC公告 ·  2024/11/07 05:14

Moomoo AI 已提取核心信息

Gilead Sciences reported strong Q3 2024 results with total revenue increasing 7% to $7.5 billion, driven by HIV product sales growth of 9% to $5.1 billion. Biktarvy sales rose 13% to $3.5 billion, while Oncology sales grew 6% to $816 million. Product sales excluding Veklury increased 7% to $6.8 billion.The company recorded a $1.75 billion IPR&D impairment charge related to Immunomedics assets, resulting in GAAP diluted EPS of $1.00 compared to $1.73 in Q3 2023. Non-GAAP diluted EPS was $2.02. Operating cash flow remained strong at $4.3 billion for the quarter.Based on strong performance, Gilead raised its full-year 2024 guidance, now expecting total product sales of $27.8-28.1 billion, up from previous guidance of $27.1-27.5 billion. The company also increased its non-GAAP EPS guidance to $4.25-4.45 from $3.60-3.90, reflecting strong topline growth and disciplined expense management.
Gilead Sciences reported strong Q3 2024 results with total revenue increasing 7% to $7.5 billion, driven by HIV product sales growth of 9% to $5.1 billion. Biktarvy sales rose 13% to $3.5 billion, while Oncology sales grew 6% to $816 million. Product sales excluding Veklury increased 7% to $6.8 billion.The company recorded a $1.75 billion IPR&D impairment charge related to Immunomedics assets, resulting in GAAP diluted EPS of $1.00 compared to $1.73 in Q3 2023. Non-GAAP diluted EPS was $2.02. Operating cash flow remained strong at $4.3 billion for the quarter.Based on strong performance, Gilead raised its full-year 2024 guidance, now expecting total product sales of $27.8-28.1 billion, up from previous guidance of $27.1-27.5 billion. The company also increased its non-GAAP EPS guidance to $4.25-4.45 from $3.60-3.90, reflecting strong topline growth and disciplined expense management.
吉利德科学发布了2024年第三季度强劲的财报，总营业收入增长了7%，达75亿美元，这得益于艾滋病毒产品销售增长9%，达51亿美元。Biktarvy的销售额增长了13%，达35亿美元，而肿瘤学销售增长了6%，达81600万美元。扣除Veklury的产品销售增长了7%，达68亿美元。公司记录了与Immunomedics资产相关的17.5亿美元的知识产权及研发减值费用，导致GAAP摊薄后每股收益为1.00美元，而2023年第三季度为1.73美元。非GAAP摊薄后每股收益为2.02美元。本季度运营现金流依然强劲，达43亿美元。基于强劲的业绩，吉利德提高了2024年的全年指引，现在预计总产品销售为278-281亿美元，较之前指引的271-275亿美元有所上调。公司还将非GAAP每股收益指引从3.60-3.90提高至4.25-4.45，反映了强劲的整体增长和严格的费用管理。
吉利德科学发布了2024年第三季度强劲的财报，总营业收入增长了7%，达75亿美元，这得益于艾滋病毒产品销售增长9%，达51亿美元。Biktarvy的销售额增长了13%，达35亿美元，而肿瘤学销售增长了6%，达81600万美元。扣除Veklury的产品销售增长了7%，达68亿美元。公司记录了与Immunomedics资产相关的17.5亿美元的知识产权及研发减值费用，导致GAAP摊薄后每股收益为1.00美元，而2023年第三季度为1.73美元。非GAAP摊薄后每股收益为2.02美元。本季度运营现金流依然强劲，达43亿美元。基于强劲的业绩，吉利德提高了2024年的全年指引，现在预计总产品销售为278-281亿美元，较之前指引的271-275亿美元有所上调。公司还将非GAAP每股收益指引从3.60-3.90提高至4.25-4.45，反映了强劲的整体增长和严格的费用管理。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Medicus Pharma
    MDCX
    -- 3.720
    Organon & Co
    OGN
    -- 14.890
    Scilex Holding
    SCLX
    -- 0.249
    艾伯维公司
    ABBV
    -- 209.520
    诺和诺德
    NVO
    -- 69.440
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点